Peptide · Recovery & Tissue Repair
BPC-157 / KPV / TB500
A three-peptide stack pairing BPC-157's local tissue repair with KPV's gut-and-skin anti-inflammatory tripeptide signal and TB-500's cell-migration, soft-tissue flexibility angle.
Available by consultation
What it is
Repair & Anti-Inflammatory
BPC-157 / KPV / TB500 combines three peptides with complementary research profiles: BPC-157 (Body Protection Compound), a 15-amino-acid peptide studied for localized connective-tissue and gut-lining repair; KPV, a lysine-proline-valine tripeptide derived from the C-terminal tail of alpha-MSH and studied specifically for anti-inflammatory activity in the gut mucosa and skin; and TB-500, a synthetic fragment of thymosin beta-4 studied for actin-driven cell migration and soft-tissue flexibility. What sets this stack apart from the plainer BPC-157 / TB-500 pairing is KPV — it adds a dedicated mucosal and systemic anti-inflammatory dimension that neither of the other two peptides supplies, one that is distinct from the skin-and-collagen focus of the GHK-Cu stacks. It is a compounded therapy, prescribed only when a licensed provider determines it is clinically appropriate for you.
Each peptide in BPC-157 / KPV / TB500 works through a different mechanism, and the reason to combine them is that they cover repair, inflammation, and flexibility as three separate levers rather than one.
BPC-157 — local repair signaling
The repair anchor. BPC-157 is studied for interacting with the VEGFR2 and nitric-oxide pathways involved in new microvessel formation, and for influencing fibroblasts and growth-factor signaling at a damaged site — research directed at feeding a healing tendon, ligament, or gut lining the local blood supply and collagen scaffolding it draws on.
KPV — anti-inflammatory tripeptide
The dimension unique to this stack. KPV is the C-terminal tripeptide of alpha-MSH, and research interest centers on how it may enter cells to dampen pro-inflammatory NF-kB signaling — studied most in the gut mucosa and skin. That inflammation-calming role is one BPC-157 and TB-500 do not provide, and it is mechanistically different from GHK-Cu's copper-driven collagen and skin-remodeling work.
TB-500 — cell migration & flexibility
The flexibility contributor. TB-500 is a fragment of thymosin beta-4 that regulates actin, the cytoskeletal protein that lets cells move. That actin-binding role is studied for helping repair cells migrate across a broader area and for soft-tissue gliding and range of motion — a movement-and-flexibility emphasis distinct from BPC-157's pinpoint local repair.
Candidacy
A considered fit, not a funnel.
BPC-157 / KPV / TB500 tends to suit people whose picture is repair plus inflammation, not repair alone — an active adult with a nagging soft-tissue issue who also deals with gut irritability or inflammatory symptoms, where KPV's anti-inflammatory layer earns its place alongside BPC-157 and TB-500. Someone whose goal is purely localized tissue repair may not need the third peptide, and anyone focused on skin, collagen, or hair goals is better matched to a GHK-Cu stack. It is intended to support recovery and is not a substitute for orthopedic, surgical, or gastroenterology care. A provider reviews your history to decide whether the full three-peptide combination fits your goals.
- Active adults with a soft-tissue issue plus gut or inflammatory symptoms
- People wanting repair and flexibility with an added KPV anti-inflammatory layer
- Those for whom BPC-157 / TB-500 alone left the inflammation piece unaddressed
- Anyone with an active or recent cancer diagnosis (angiogenic and cell-migration signaling are theoretical concerns)
- People who are pregnant or breastfeeding
- Anyone whose goals are primarily skin, collagen, or hair — better matched to a GHK-Cu stack
Expected Timeline
What to expect
BPC-157 / KPV / TB500 is typically run as a focused, provider-directed course rather than an open-ended regimen — concentrated through an active repair-and-inflammation window, then wound down as the target area and symptoms settle.
- 01
Weeks 1-2
Initiation
Your provider establishes the protocol for all three peptides — often subcutaneous, with route and timing tuned to whether the emphasis is soft-tissue repair or KPV-led gut-focused anti-inflammatory support — and confirms tolerability before continuing.
- 02
Weeks 3-6
Active repair & calming
The core window where BPC-157 and TB-500 target tissue repair and flexibility while KPV works on the inflammatory picture. Many protocols hold a steady cadence here while you and your provider track how the target area and any gut or skin symptoms respond.
- 03
Weeks 6-8+
Taper & reassess
Rather than continuing indefinitely, courses are commonly wound down and reassessed. Your provider decides whether a maintenance approach, a pause, or a stop makes sense — and whether all three peptides are still warranted.
Response varies from person to person, and this is a compounded, provider-directed stack. Your specific peptides, doses, routes, and duration are set and adjusted by your prescriber — the cadence above is illustrative, not a promise of any particular result.
The Science
Why clinicians reach for it.
The evidence for each peptide in BPC-157 / KPV / TB500 is largely preclinical and early-stage. We describe the direction of research honestly — no invented trials, no promised outcomes — and note where each component's interest actually lies.
Three separate research threads
BPC-157's literature centers on gastrointestinal protection and connective-tissue healing; KPV's on anti-inflammatory activity in the gut mucosa and skin as an alpha-MSH fragment; TB-500's on actin regulation and cell migration. This stack combines three distinct threads rather than reinforcing a single one.
KPV is what differentiates it
The anti-inflammatory tripeptide is the reason to consider this over a plain BPC-157 / TB-500 pairing. KPV is studied for calming inflammatory signaling — a mechanism genuinely different from GHK-Cu's copper-carrier role in skin and collagen remodeling, so the two should not be treated as interchangeable.
Not FDA-approved
None of these three peptides is an FDA-approved drug; they are available only through compounding when a licensed provider deems it appropriate. This stack should be viewed as an emerging, supportive therapy — not an established treatment for any condition.
Our Standard of Care
Real transformation, with a friendly team that stands by you every step.
- 01.Provider-Supervised
- Licensed providers review your health profile and guide every treatment decision. You only move forward when a plan is right for you.
- 02.Personalized Plans
- GLP-1 and peptide protocols are titrated to your biology and your goals. No one-size-fits-all, no guesswork.
- 03.We Stand By You
- From eligibility review to ongoing check-ins, our care team supports you throughout your transformation — discreet shipping and secure messaging included.
Clinical Safety
No therapy is right for everyone.
What to know
Reported effects across these peptides are generally mild and may include irritation, redness, or discomfort at the injection site, and occasional lightheadedness, fatigue, or nausea. Because human safety data for BPC-157, KPV, and TB-500 is limited — and because combining peptides can broaden the range of possible responses — any new or persistent symptom should be reported to your provider promptly.
Contraindications
Not appropriate during pregnancy or breastfeeding, or for anyone with a known hypersensitivity to any of the three peptides or the diluent. Given BPC-157's angiogenic signaling and TB-500's role in cell migration, the stack is generally avoided in anyone with an active or recent malignancy. Share your full medical history — including any cancer history and any inflammatory or autoimmune conditions — so your provider can assess whether all three peptides are suitable for you.
MagsRX protocols are prepared by partner compounding pharmacies in the United States. Compounding pharmacies are regulated by both state boards and the FDA and have been part of American medicine since long before mass-manufactured drugs existed. The active ingredient is prepared per your protocol — supervised by your provider — and delivered direct to your door.
Frequently Asked
Questions worth asking before you begin.
The difference is KPV. BPC-157 / TB-500 covers local repair and soft-tissue flexibility, but neither peptide is an anti-inflammatory in its own right. KPV — a tripeptide from alpha-MSH studied for calming inflammatory signaling in the gut and skin — adds that third dimension. If your picture includes inflammation or gut irritability alongside a soft-tissue issue, this stack addresses that layer in a way the two-peptide version does not.
No. GHK-Cu is a copper-carrying tripeptide whose research centers on skin, collagen, and tissue remodeling — an aesthetic and structural focus. KPV's studied role is anti-inflammatory, concentrated in the gut mucosa and skin inflammation rather than collagen building. They are different molecules with different mechanisms, which is why this stack and the GHK-Cu stacks are matched to different goals.
Because each covers a different lever — BPC-157 for local repair, TB-500 for flexibility and cell migration, KPV for inflammation. For someone whose situation spans all three, a provider may find the combination a closer fit than any single peptide. Whether you need all three, or would do just as well on fewer, is a clinical decision your prescriber makes after reviewing your history.
Explore More
Other therapies to consider.
Tissue RepairBPC-157
A body-protection pentadecapeptide studied for how it may support the slow-healing places — a strained tendon, an irritable gut lining, a joint that lingers.
Learn more →- Recovery Stack
BPC-157 / TB500
A two-peptide recovery stack that pairs BPC-157's localized repair focus with TB-500's systemic reach — so support isn't confined to one strained spot but extends across the soft tissue that moves with it.
Learn more → - Tissue Repair
BPC-157 Acetate
The same BPC-157 pentadecapeptide, prepared as the acetate salt — the biocompatible counter-ion chosen for a clean compounded preparation that avoids residual TFA.
Learn more →
Begin
BPC-157 / KPV / TB500 begins with a short assessment.
A licensed provider reviews every order and prescribes only if it is clinically appropriate for you. Your therapy is prepared by a partner compounding pharmacy and delivered discreetly to your door.